Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2026 09:30 ET | Source: Beacon Biosignals

Beacon Biosignals Unifies Brands, Bringing CleveMed and SleepView® Under the Beacon Name

CleveMed has joined Beacon Biosignals to advance what is possible in at-home sleep diagnostics.
May 20, 2026 11:17 ET | Source: Leafwell, Inc.

Leafwell Advances Medical Cannabis as Clinically Validated Solution for Cancer-Related Symptoms and Chronic Pain, Supports Employer-Sponsored Mental Health Benefits

Leafwell Advances Medical Cannabis as Clinically Validated Solution for Cancer-Related Symptoms and Chronic Pain, Supports Employer-Sponsored Mental Health
December 16, 2025 06:30 ET | Source: Beacon Biosignals

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

Beacon Biosignals partners with Harmony Biosciences to quantitatively measure excessive daytime sleepiness in phase 3 clinical trial.
November 19, 2025 06:30 ET | Source: Beacon Biosignals

Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year...
June 12, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

NEW YORK and MELBOURNE, Australia, June 12, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing...
June 03, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way...
May 28, 2025 07:00 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

MELBOURNE, Australia and NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for...
May 20, 2025 07:30 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

NEW YORK and MELBOURNE, Australia, May 20, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company pioneering the...
May 15, 2025 08:00 ET | Source: Incannex Healthcare

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral...
September 10, 2024 08:00 ET | Source: ResMed Inc.

Vaping Expected to Increase COPD Health and Economic Burden by 2050

Vaping Expected to Increase COPD Health and Economic Burden by 2050 New ResMed-supported research presented at ERS 2024